NBY
Price
$0.63
Change
-$0.01 (-1.56%)
Updated
Feb 21 closing price
Capitalization
3.08M
WINT
Price
$4.35
Change
-$0.45 (-9.37%)
Updated
Feb 21 closing price
Capitalization
3.26M
Ad is loading...

NBY vs WINT

Header iconNBY vs WINT Comparison
Open Charts NBY vs WINTBanner chart's image
NovaBay Pharmaceuticals
Price$0.63
Change-$0.01 (-1.56%)
Volume$82.16K
Capitalization3.08M
Windtree Therapeutics
Price$4.35
Change-$0.45 (-9.37%)
Volume$297.68K
Capitalization3.26M
NBY vs WINT Comparison Chart
Loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WINT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NBY vs. WINT commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBY is a Hold and WINT is a Buy.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (NBY: $0.67 vs. WINT: $0.11)
Brand notoriety: NBY and WINT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBY: 7% vs. WINT: 91%
Market capitalization -- NBY: $3.08M vs. WINT: $3.26M
NBY [@Biotechnology] is valued at $3.08M. WINT’s [@Biotechnology] market capitalization is $3.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBY’s FA Score shows that 0 FA rating(s) are green whileWINT’s FA Score has 1 green FA rating(s).

  • NBY’s FA Score: 0 green, 5 red.
  • WINT’s FA Score: 1 green, 4 red.
According to our system of comparison, both NBY and WINT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBY’s TA Score shows that 4 TA indicator(s) are bullish while WINT’s TA Score has 4 bullish TA indicator(s).

  • NBY’s TA Score: 4 bullish, 3 bearish.
  • WINT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both NBY and WINT are a good buy in the short-term.

Price Growth

NBY (@Biotechnology) experienced а +3.26% price change this week, while WINT (@Biotechnology) price change was -31.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

NBY is expected to report earnings on May 11, 2023.

WINT is expected to report earnings on May 17, 2023.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WINT($3.26M) has a higher market cap than NBY($3.08M). NBY YTD gains are higher at: 11.681 vs. WINT (-68.537). WINT has more cash in the bank: 917K vs. NBY (776K). NBY has less debt than WINT: NBY (1.26M) vs WINT (2.01M).
NBYWINTNBY / WINT
Capitalization3.08M3.26M94%
EBITDA-6.52MN/A-
Gain YTD11.681-68.537-17%
P/E RatioN/A0.83-
Revenue13.8MN/A-
Total Cash776K917K85%
Total Debt1.26M2.01M63%
FUNDAMENTALS RATINGS
NBY vs WINT: Fundamental Ratings
NBY
WINT
OUTLOOK RATING
1..100
78
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
6398
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBY's Valuation (41) in the Biotechnology industry is in the same range as WINT (60). This means that NBY’s stock grew similarly to WINT’s over the last 12 months.

NBY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as WINT (100). This means that NBY’s stock grew similarly to WINT’s over the last 12 months.

WINT's SMR Rating (99) in the Biotechnology industry is in the same range as NBY (100). This means that WINT’s stock grew similarly to NBY’s over the last 12 months.

NBY's Price Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for WINT (98). This means that NBY’s stock grew somewhat faster than WINT’s over the last 12 months.

WINT's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for NBY (100). This means that WINT’s stock grew significantly faster than NBY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBYWINT
RSI
ODDS (%)
Bearish Trend 6 days ago
90%
Bullish Trend 6 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 6 days ago
81%
Momentum
ODDS (%)
Bullish Trend 6 days ago
76%
Bearish Trend 6 days ago
90%
MACD
ODDS (%)
Bearish Trend 6 days ago
90%
Bullish Trend 6 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 18 days ago
82%
Bullish Trend 13 days ago
75%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
89%
N/A
Aroon
ODDS (%)
Bullish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Ad is loading...
NBY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WINT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

NBY and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBY has been closely correlated with CDTX. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NBY jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBY
1D Price
Change %
NBY100%
+1.54%
CDTX - NBY
93%
Closely correlated
+0.25%
NCNA - NBY
93%
Closely correlated
+3.29%
WINT - NBY
92%
Closely correlated
-20.01%
SNPX - NBY
91%
Closely correlated
-6.31%
RNAC - NBY
91%
Closely correlated
-0.76%
More

WINT and

Correlation & Price change

A.I.dvisor indicates that over the last year, WINT has been closely correlated with CDTX. These tickers have moved in lockstep 94% of the time. This A.I.-generated data suggests there is a high statistical probability that if WINT jumps, then CDTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WINT
1D Price
Change %
WINT100%
-20.01%
CDTX - WINT
94%
Closely correlated
+0.25%
NCNA - WINT
92%
Closely correlated
+3.29%
SNPX - WINT
92%
Closely correlated
-6.31%
NBY - WINT
92%
Closely correlated
+1.54%
AGEN - WINT
91%
Closely correlated
+0.28%
More